Indoco Remedies

Indoco Remedies

260.95
-3.50
(-1.32%)
hide
Key Fundamentals
Add Ratio
Market Cap
2,407.20 Cr
EPS
-8.46
PE Ratio
-20.84
Dividend Yield
0.08 %
Industry
Healthcare
52 Week High
355.00
52 Week Low
190.00
PB Ratio
2.45
Debt to Equity
0.78
Analyst Rating and Forecast
- By Refinitiv from5 analysts
HOLD
Analysts have suggested that investors can hold this stock
Buy
Buy0.0 %
0.0 %
Hold
Hold+80.00 %
+80.00 %
Sell
Sell+20.00 %
+20.00 %
Forecast For
Actual

Company News

View All News
Caret
positive
Indoco Remedies reported a net loss of 79 million rupees in Q2, an improvement from the previous year's loss of 96 million rupees. The company's revenue increased to 4.8 billion rupees compared to 4.3 billion rupees in the same period last year. EBITDA rose to 431 million rupees from 403 million rupees year-over-year, though the EBITDA margin declined slightly to 8.9% from 9.3% in the previous year.
positive
The USFDA completed an inspection of Indoco Remedies' API manufacturing facility at Patalganga with zero observations. The company views this outcome as a reflection of its commitment to quality and regulatory compliance.
neutral
Indoco Remedies has entered into a sale and leaseback agreement valued at ₹24.65 crore with OPC Asset Solution. The agreement covers the company's Waluj facility and Anacipher CRO, with the lease arrangement extending until 2035.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,691.40
#1 4,05,823.50
38.74
#1 54,729.00
9.71
#1 10,980
2.89
55.98
6,656.50
1,76,709.20
71.11
9,712.00
18.67
2,191
35.10
58.39
1,505.70
1,21,623.50
22.36
28,409.50
7.12
5,291
3.71
40.84
3,580.00
1,21,163.50
60.51
11,539.40
6.99
1,911
30.46
50.54
1,205.40
1,00,604.30
#1 17.53
33,741.20
16.73
5,725
-0.38
37.06
944.10
94,998.60
18.88
23,511.00
18.55
4,615
34.60
33.87
2,261.80
93,357.70
52.66
12,744.20
#1 20.90
2,007
-21.05
25.15
1,971.80
90,062.90
20.71
22,909.50
13.74
3,306
#1 72.75
53.33
5,668.50
67,775.40
29.08
13,458.30
3.70
2,216
21.39
63.91
1,123.80
65,270.50
19.24
32,345.60
9.43
3,484
3.81
53.78
Growth Rate
Revenue Growth
-8.58 %
Net Income Growth
-180.41 %
Cash Flow Change
-38.91 %
ROE
-187.53 %
ROCE
-104.41 %
EBITDA Margin (Avg.)
-54.92 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
213
237
249
250
248
287
284
264
267
324
334
297
382
374
349
401
396
405
412
429
417
478
461
462
425
432
404
386
433
473
Expenses
206
224
238
224
230
260
255
239
227
268
272
250
300
300
285
329
337
345
337
363
365
410
405
401
384
392
399
391
422
442
EBITDA
7
13
11
26
18
27
30
25
40
56
62
47
82
74
65
72
60
60
74
66
52
68
56
61
42
40
6
-5
10
30
Operating Profit %
3 %
5 %
4 %
9 %
7 %
9 %
10 %
9 %
15 %
17 %
18 %
15 %
21 %
19 %
18 %
18 %
15 %
15 %
18 %
15 %
12 %
13 %
12 %
9 %
10 %
9 %
1 %
-2 %
2 %
6 %
Depreciation
17
18
18
20
17
18
18
18
19
19
17
19
22
20
19
18
20
16
17
18
20
21
24
26
28
29
29
29
30
32
Interest
7
5
4
5
6
5
7
8
6
6
6
5
4
3
4
3
4
5
7
9
8
8
10
12
14
18
16
18
26
25
Profit Before Tax
-12
-10
4
9
-0
10
11
8
24
37
38
34
61
65
51
60
48
67
38
39
34
46
23
33
7
-5
-31
-46
-37
-14
Tax
0
-3
-1
-2
-2
2
2
2
7
11
12
9
22
23
18
19
10
18
10
13
10
11
7
11
5
5
-3
-4
-0
-4
Net Profit
-12
-7
5
12
2
8
9
5
17
26
25
25
40
42
33
41
39
50
28
26
24
35
16
22
2
-10
-28
-41
-36
-9
EPS in ₹
-1.32
-0.81
0.57
1.25
0.20
0.85
0.99
0.58
1.85
2.78
2.75
2.71
4.30
4.52
3.58
4.39
4.19
5.40
3.05
2.80
2.62
3.82
1.69
2.39
0.20
-1.09
-3.08
-4.48
-3.94
-1.00

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
846
941
1,197
1,238
1,258
1,272
1,315
1,486
1,658
2,145
2,430
Fixed Assets
340
374
440
489
468
590
570
555
678
954
997
Current Assets
385
465
572
539
538
563
623
774
814
955
1,001
Capital Work in Progress
63
55
91
136
185
51
68
122
114
125
321
Investments
0
16
0
0
0
0
0
0
3
9
2
Other Assets
443
496
666
614
605
631
677
809
864
1,057
1,111
Total Liabilities
846
941
1,197
1,238
1,258
1,272
1,315
1,486
1,658
2,145
2,430
Current Liabilities
262
303
390
417
446
459
407
425
425
612
808
Non Current Liabilities
65
61
155
146
152
133
139
157
205
422
604
Total Equity
519
577
651
675
661
680
769
905
1,028
1,111
1,018
Reserve & Surplus
500
558
633
657
642
661
751
886
1,010
1,092
1,004
Share Capital
18
18
18
18
18
18
18
18
18
18
18

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
1
-0
50
-52
12
3
-14
8
-7
4
-3
Investing Activities
-88
-111
-171
-135
-104
-56
-67
-121
-208
-432
-339
Operating Activities
109
112
89
123
132
123
82
174
179
155
95
Financing Activities
-20
-2
132
-39
-16
-64
-30
-44
23
280
241

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
58.69 %
58.69 %
58.69 %
58.69 %
58.69 %
58.69 %
58.69 %
58.69 %
58.69 %
58.74 %
58.74 %
58.72 %
58.75 %
58.75 %
58.80 %
58.90 %
58.90 %
58.90 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.12 %
0.12 %
1.59 %
1.69 %
1.91 %
1.47 %
1.70 %
1.25 %
1.24 %
1.22 %
1.25 %
DIIs
18.88 %
18.80 %
17.22 %
17.23 %
17.64 %
17.52 %
17.33 %
18.07 %
17.29 %
17.78 %
19.56 %
19.41 %
18.67 %
18.24 %
18.90 %
18.75 %
18.96 %
18.16 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
15.92 %
15.92 %
17.32 %
17.87 %
17.87 %
17.23 %
16.85 %
16.74 %
16.48 %
16.84 %
15.24 %
15.33 %
16.29 %
16.30 %
16.07 %
15.99 %
15.79 %
16.40 %
Others
6.52 %
6.59 %
6.78 %
6.21 %
5.80 %
6.57 %
7.13 %
6.39 %
7.42 %
5.04 %
4.77 %
4.62 %
4.81 %
5.01 %
4.99 %
5.12 %
5.14 %
5.29 %
No of Share Holders
21,508
24,518
34,746
37,279
37,863
38,498
38,072
35,713
34,731
36,588
32,600
33,201
34,511
34,416
34,676
34,497
33,129
33,319

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 1.6 1 0.3 0.3 1.5 2.25 2.25 1.5 0.2
Dividend Yield (%) 0.00 0.75 0.49 0.14 0.1 0.4 0.69 0.68 0.64 0.08

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
21 Sept 2021 DIVIDEND Dividend
₹ 1.50 /share
17 Sept 2021 358.65 473.05
16 Sept 2022 DIVIDEND Dividend
₹ 0.75 /share
14 Sept 2022 331.60 359.35
15 Sept 2022 DIVIDEND Dividend
₹ 1.50 /share
14 Sept 2022 331.60 365.20
19 Sept 2023 DIVIDEND Dividend
₹ 2.25 /share
18 Sept 2023 347.80 356.80
19 Sept 2024 DIVIDEND Dividend
₹ 1.50 /share
19 Sept 2024 327.55 369.65
26 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Sept 2024 365.50 365.50
24 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
24 Oct 2024 336.65 319.95
21 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
21 Jan 2025 326.65 335.15
22 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 May 2025 251.12 261.58
24 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
24 Jul 2025 325.90 310.05
04 Sept 2025 DIVIDEND Dividend
₹ 0.20 /share
04 Sept 2025 261.58 282.60
11 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
11 Sept 2025 293.70 276.85
06 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Nov 2025 296.85 273.20

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication1 day ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome2 days ago
Financial Results For The Quarter And Half Year Ended 30Th September 20252 days ago
Board Meeting Outcome for Outcome Of Board Meeting Held On 06Th November 20252 days ago
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -Corporate Guarantee For Warren Remedies Private Limited Wholly Owned Subsidiary Of The Company10 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 17, 2025
Clarification To BSE- Movement In VolumeOct 14, 2025
Clarification sought from Indoco Remedies LtdOct 14, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Reg 29 Of SEBI (LODR) Regulations 2015Oct 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 10, 2025
Closure of Trading WindowSep 30, 2025
Announcement under Regulation 30 (LODR)-Credit RatingSep 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 19, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 12, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 11, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsAug 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 15, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 14, 2025
Reg. 34 (1) Annual Report.Aug 14, 2025
Notice Of 78Th Annual General Meeting And Annual Report For The Financial Year 2024-25Aug 14, 2025
Intimation Of Cut-Off Date For E-Voting Book Closure And Record Date For DividendAug 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 08, 2025
Announcement under Regulation 30 (LODR)-Credit RatingAug 04, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsAug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 30, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 24, 2025
Financial Results For The Quarter Ended 30Th June 2025Jul 24, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 24Th July 2025Jul 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 16, 2025
Board Meeting Intimation for Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended 30-06-2025.Jul 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 03, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 03, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 03, 2025
Closure of Trading WindowJun 27, 2025
Intimation To Shareholders Holding Shares In Physical Mode Regarding Mandatory Furnishing Of PAN KYC And Bank Details As Per SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 Dated May 07 2024 And SEBI Circular Bearing Reference No. SEBI/HO/MIRSDJun 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 19, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 13, 2025
Announcement Under Regulation 30 (LODR):- Order For Drop Of Proceeding Under GST Act 2017Jun 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 12, 2025
Order For Drop Of ProceedingJun 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 03, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
DSP Healthcare Fund Direct - Growth
0.00%
-3233474
-3.07%
-2.77%
Nippon India Small Cap Fund Direct- Growth
0.00%
-2594559
-0.11%
-0.11%
Franklin India Small Cap Fund Direct-Growth
0.00%
-2025592
-0.45%
-0.41%
Nippon India Pharma Fund Direct-Growth
0.00%
-1834924
-0.66%
-0.59%
HDFC Value Fund Direct Plan-Growth
0.00%
-1534403
-0.62%
-0.33%
DSP Multicap Fund Direct - Growth
0.00%
-462465
-0.53%
-0.50%
Tata India Innovation Fund Direct-Growth
0.00%
-310342
-0.53%
-0.48%
Tata India Pharma & Healthcare Fund Direct-Growth
0.00%
-19408
-0.04%
-0.87%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.00%
-498
-0.08%
-0.07%
HDFC Multi Cap Fund Direct - Growth
0.00%
0
0.00%
-0.10%
ICICI Prudential Smallcap Fund Direct Plan-Growth
0.00%
0
0.00%
0.00%
Quant Small Cap Fund Direct Plan-Growth
0.38%
0
-0.03%
-0.01%

Technical Indicators

RSI(14)
Neutral
31.97
ATR(14)
Less Volatile
10.77
STOCH(9,6)
Neutral
21.02
STOCH RSI(14)
Oversold
0.70
MACD(12,26)
Bearish
-2.02
ADX(14)
Weak Trend
16.85
UO(9)
Bullish
28.71
ROC(12)
Downtrend And Accelerating
-9.01
WillR(14)
Oversold
-94.31